Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study is designed to assess the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with systemic sclerosis (SSc). Approximately 45 patients at approximately 40 sites will be randomized in a 2:1 ratio to receive either 10 mg/kg CM-101 or placebo.
Epistemonikos ID: 87087c90f44d9a00786fc453b9e44141056f6428
First added on: May 15, 2024